Source:http://linkedlifedata.com/resource/pubmed/id/11830473
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
4
|
| pubmed:dateCreated |
2002-2-6
|
| pubmed:abstractText |
The postinduction level of minimal residual disease (MRD) was quantified with a competitive polymerase chain reaction (PCR) technique in 104 children with acute lymphoblastic leukemia (ALL) diagnosed between June 1993 and January 1998 and followed for a median of 4.2 years. A significant correlation was found between the MRD level on day 15 (D15) and day 29 (D29) after the start of induction therapy (r(s) = 0.70, P <.0001). The 15 patients with T-cell disease had higher D29 MRD than those with B-lineage ALL (P =.01). Age was positively related to D29 MRD (r(s) = 0.32, P =.001). The 16 patients who had a relapse had higher D15 and D29 MRD levels than the patients who stayed in remission (median levels D15, 1% versus 0.1%, P =.03; D29, 0.4% versus 0.01%, P =.0001). No patients with a MRD level less than 0.01% on D29 have so far had a relapse, whereas the 7-year probability of event-free survival for patients with higher MRD levels was 0.52 (P =.0007). The group of patients with a D29 MRD less than 0.01% included patients with T-cell disease, white blood cell count more than 50 x 10(9)/L at diagnosis, or age 10 years or older, and could not be identified by up-front criteria. The best-fit Cox model to predict the risk of relapse included D29 MRD (P =.004) and age (P =.009). These findings indicate that with the present treatment protocol MRD quantification at an early stage of therapy identifies patients with a very low risk of relapse. Further trials are needed to reveal whether such patients with D29 MRD less than 0.01% can be cured with less intensive chemotherapy, which would reduce the risk of serious late effects as well as the costs of therapy.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
AIM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Feb
|
| pubmed:issn |
0006-4971
|
| pubmed:author |
pubmed-author:ClausenNielsN,
pubmed-author:ForestierErikE,
pubmed-author:JonssonOlafur GOG,
pubmed-author:MadsenHans OHO,
pubmed-author:Nordic Society for Pediatric Hematology and Oncology,
pubmed-author:NyvoldCharlotteC,
pubmed-author:RyderLars PLP,
pubmed-author:SchmiegelowKjeldK,
pubmed-author:SeyfarthJeanetteJ,
pubmed-author:SvejgaardArneA,
pubmed-author:WesenbergFinnF
|
| pubmed:issnType |
Print
|
| pubmed:day |
15
|
| pubmed:volume |
99
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
1253-8
|
| pubmed:dateRevised |
2007-11-15
|
| pubmed:meshHeading |
pubmed-meshheading:11830473-Adolescent,
pubmed-meshheading:11830473-Child,
pubmed-meshheading:11830473-Child, Preschool,
pubmed-meshheading:11830473-Female,
pubmed-meshheading:11830473-Follow-Up Studies,
pubmed-meshheading:11830473-Humans,
pubmed-meshheading:11830473-Immunoglobulin Heavy Chains,
pubmed-meshheading:11830473-Infant,
pubmed-meshheading:11830473-Male,
pubmed-meshheading:11830473-Models, Biological,
pubmed-meshheading:11830473-Neoplasm, Residual,
pubmed-meshheading:11830473-Polymerase Chain Reaction,
pubmed-meshheading:11830473-Precursor Cell Lymphoblastic Leukemia-Lymphoma,
pubmed-meshheading:11830473-Prognosis,
pubmed-meshheading:11830473-Receptors, Antigen, T-Cell,
pubmed-meshheading:11830473-Recurrence,
pubmed-meshheading:11830473-Risk Factors,
pubmed-meshheading:11830473-Scandinavia,
pubmed-meshheading:11830473-Time Factors,
pubmed-meshheading:11830473-Treatment Outcome
|
| pubmed:year |
2002
|
| pubmed:articleTitle |
Precise quantification of minimal residual disease at day 29 allows identification of children with acute lymphoblastic leukemia and an excellent outcome.
|
| pubmed:affiliation |
Department of Clinical Immunology and Department of Pediatrics, National University Hospital, Rigshospitalet, Copenhagen, Denmark.
|
| pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|